Abstract 3894: Determination of the efficacious Entrectinib exposures required for pathway inhibition and anti-tumor activity in a subcutaneous and intracranial<i>TPM3-NTRK1</i>mutant tumor model

Authors: Cecile C. de la Cruz, Thomas Hunsaker, Faye Vazvaei, Dragomir Draganov, Li Yu, Mark Merchant

Published: 2019-08-07

DOI: 10.1158/1538-7445.am2019-3894

Source: Full article